Dr.Datsons Labs Ltd
Dr.Datsons Labs Ltd is an India-based integrated pharmaceutical company. The company is engaged in the manufacturing and marketing capabilities in contract research and manufacturing services, and active pharmaceutical ingredients.
- Market Cap ₹ Cr.
- Current Price ₹ 6.40
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 50.2
- Dividend Yield 0.00 %
- ROCE 5.03 %
- ROE 0.19 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 0.13 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.06% over last 3 years.
- Earnings include an other income of Rs.17.1 Cr.
- Dividend payout has been low at 8.42% of profits over last 3 years
- Company has high debtors of 317 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 15m | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | TTM | |
---|---|---|---|---|---|---|---|---|---|
-0 | 22 | 90 | 162 | 320 | 480 | 521 | 421 | 507 | |
-0 | 17 | 79 | 132 | 250 | 375 | 415 | 364 | 488 | |
Operating Profit | -0 | 5 | 11 | 29 | 71 | 105 | 106 | 57 | 20 |
OPM % | 22% | 12% | 18% | 22% | 22% | 20% | 14% | 4% | |
-0 | -0 | 0 | 1 | 0 | 2 | -40 | 8 | 17 | |
Interest | -0 | 1 | 3 | 6 | 14 | 29 | 43 | 43 | 37 |
Depreciation | -0 | 0 | 1 | 1 | 3 | 16 | 20 | 20 | 9 |
Profit before tax | -0 | 4 | 8 | 23 | 55 | 63 | 3 | 1 | -9 |
Tax % | 37% | 35% | 34% | 34% | 35% | 80% | 48% | ||
-0 | 2 | 5 | 15 | 36 | 41 | 1 | 1 | -6 | |
EPS in Rs | 29.55 | 0.40 | 0.21 | -1.93 | |||||
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | 25% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | 10% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -33% |
3 Years: | -74% |
TTM: | -144% |
Stock Price CAGR | |
---|---|
10 Years: | -3% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 9% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Sep 2014 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 2 | 5 | 6 | 8 | 14 | 14 | 32 | 53 |
Reserves | -0 | 2 | 7 | 44 | 127 | 336 | 296 | 376 | 475 |
1 | 12 | 38 | 60 | 139 | 299 | 550 | 495 | 366 | |
0 | 11 | 11 | 25 | 22 | 70 | 186 | 360 | 164 | |
Total Liabilities | 1 | 28 | 61 | 135 | 295 | 718 | 1,045 | 1,263 | 1,058 |
-0 | 11 | 13 | 47 | 70 | 214 | 208 | 188 | 186 | |
CWIP | 1 | -0 | -0 | 4 | 47 | 144 | 164 | 179 | 343 |
Investments | -0 | 0 | 0 | 0 | 0 | 1 | 2 | 213 | 213 |
0 | 17 | 47 | 84 | 178 | 359 | 670 | 683 | 316 | |
Total Assets | 1 | 28 | 61 | 135 | 295 | 718 | 1,045 | 1,263 | 1,058 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
---|---|---|---|---|---|---|---|---|
0 | -2 | -22 | 1 | -46 | -46 | 40 | 135 | |
-1 | -11 | -3 | -39 | -68 | -256 | -36 | -226 | |
1 | 13 | 26 | 38 | 114 | 305 | 205 | -120 | |
Net Cash Flow | 0 | 0 | 1 | 0 | -0 | 3 | 208 | -211 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 205 | 125 | 98 | 103 | 153 | 191 | 317 | |
Inventory Days | 63 | 76 | 107 | 129 | 142 | 157 | 194 | |
Days Payable | -0 | -0 | 46 | -9 | 41 | 150 | 326 | |
Cash Conversion Cycle | 269 | 201 | 158 | 242 | 253 | 198 | 185 | |
Working Capital Days | 110 | 150 | 135 | 183 | 228 | 202 | 293 | |
ROCE % | 52% | 31% | 36% | 36% | 20% | 12% | 5% |
Documents
Announcements
No data available.